Mental Health In The Medicare Part D Drug Benefit: A New Regulatory Model?
- 1 May 2006
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 25 (3), 707-719
- https://doi.org/10.1377/hlthaff.25.3.707
Abstract
The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 represents the most significant expansion of Medicare benefits since the program's inception and has important implications for mental health. Medicare will become a major payer for psychotropic medications through the new prescription drug benefit. The structure of the drug benefit's delivery system creates incentives for plans to underprovide medications, like psychotropic drugs, that are used persistently and are associated with high expected costs. Regulators have put policies in place to counteract these incentives. This paper examines these strategies' likely success and suggests additional approaches to be considered.Keywords
This publication has 20 references indexed in Scilit:
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- The Exclusion of Benzodiazepine Coverage in Medicare: Simple Steps for Avoiding a Public Health CrisisPsychiatric Services, 2005
- Mental Health Policy and Psychotropic DrugsThe Milbank Quarterly, 2005
- Medicaid Policies To Contain Psychiatric Drug CostsHealth Affairs, 2005
- Prescription Drugs And The Changing Patterns Of Treatment For Mental Disorders, 1996–2001Health Affairs, 2005
- Adverse Selection and the Challenges to Stand-Alone Prescription Drug InsuranceForum for Health Economics and Policy, 2004
- Managing Psychotropic Drug Costs: Will Formularies Work?Health Affairs, 2003
- The deliberate misdiagnosis of major depression in primary careArchives of Family Medicine, 1994
- Medicare Financing for Mental Health CareHealth Affairs, 1990
- Outpatient benefits for mental health services in Medicare: Alignment with the private sector?American Psychologist, 1989